MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients

MAIA Biotechnology, Inc. MAIA on Thursday revealed updated data from its THIO-101 pivotal Phase 2 clinical trial.The trial is evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron Pharmaceutical Inc’s REGN immune checkpoint inhibitor (CPI) cemiplimab (Libtayo) for advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy.As of May 15, third line (3L) data showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who rec ...